MBX
MBX Biosciences, Inc.
Key Financials
Net Income
$-86971000
↓ 40.5%
Operating Income
$-98055000
↓ 43.8%
Shareholders' Equity
$369.2M
↑ 43.4%
EPS (Diluted)
$-2.38
↑ 59.1%
Cash & Equivalents
$75.3M
↑ 52.6%
Total Liabilities
$15.9M
↑ 43.5%
Total Assets
$385.1M
↑ 43.4%
Operating Cash Flow
$-79949000.00
↓ 46.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 144 | 8/17/2026 | View on SEC |
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13D/A | 8/10/2026 | View on SEC |
| SCHEDULE 13D/A | 8/10/2026 | View on SEC |
| 10-Q | 8/6/2026 | View on SEC |
| 8-K | 8/6/2026 | View on SEC |
| 4 | 8/5/2026 | View on SEC |
| 144 | 8/4/2026 | View on SEC |
| 144 | 8/4/2026 | View on SEC |
| 4 | 8/4/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MBX |
| Company Name | MBX Biosciences, Inc. |
| CIK | 1776111 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 3179893100 |